COVID-19 Breakthrough Infections and Transmission Risk: Real-World Data Analyses from Germany's Largest Public Health Department (Cologne)

被引:18
|
作者
Hsu, Lea [1 ,2 ]
Gruene, Barbara [1 ]
Buess, Michael [1 ]
Joisten, Christine [1 ,3 ]
Klobucnik, Jan [1 ]
Niessen, Johannes [1 ]
Patten, David [1 ]
Wolff, Anna [1 ]
Wiesmueller, Gerhard A. [1 ,2 ]
Kossow, Annelene [1 ,4 ]
Hurrass, Julia [1 ]
机构
[1] Publ Hlth Dept Cologne, Infekt & Umwelthyg, D-50667 Cologne, Germany
[2] Rhein Westfal TH Aachen, Univ Hosp, Inst Occupat Med & Social Med, Med Fac, D-52056 Aachen, Germany
[3] German Sport Univ Cologne, Inst Movement & Neurosci, Dept Phys Act Publ Hlth, Sportpk Mungersdorf 6, D-50933 Cologne, Germany
[4] Univ Hosp Muenster, Inst Hyg, D-48149 Munster, Germany
关键词
COVID-19; vaccination; breakthrough infections; SARS-CoV-2; pandemic; transmission; VACCINE;
D O I
10.3390/vaccines9111267
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background and Methods: Vaccination is currently considered the most successful strategy for combating the SARS-CoV-2 virus. According to short-term clinical trials, protection against infection is estimated to reach up to 95% after complete vaccination (& GE;14 days after receipt of all recommended COVID-19 vaccine doses). Nevertheless, infections despite vaccination, so-called breakthrough infections, are documented. Even though they are more likely to have a milder or even asymptomatic course, the assessment of further transmission is highly relevant for successful containment. Therefore, we calculated the real-world transmission risk from fully vaccinated patients (vaccination group, VG) to their close contacts (CP) compared with the risk from unvaccinated reference persons matched according to age, sex, and virus type (control group = CG) utilizing data from Cologne's health department. Results: A total of 357 breakthrough infections occurred among Cologne residents between 27 December 2020 (the date of the first vaccination in Cologne) and 6 August 2021. Of the 979 CPs in VG, 99 (10.1%) became infected. In CG, 303 of 802 CPs (37.8%) became infected. Factors promoting transmission included non-vaccinated status (beta = 0.237; p < 0.001), male sex (beta = 0.079; p = 0.049), the presence of symptoms (beta = -0.125; p = 0.005), and lower cycle threshold value (beta = -0.125; p = 0.032). This model explained 14.0% of the variance (corr. R-2). Conclusion: The number of transmissions from unvaccinated controls was three times higher than from fully vaccinated patients. These real-world data underscore the importance of vaccination in enabling the relaxation of stringent and restrictive general pandemic control measures.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Performance of the US Food and Drug Administration's COVID-19 Disease Severity Categorization for Use in Real-World Data
    Perez-Vilar, Silvia
    Hua, Wei
    Kwist, Andrew
    Ma, Yuxin
    Dong, Diane
    Zhang, Rongping
    Ma, Yong
    Chavez, Andrea J.
    Huang, Nina
    Sheikh, Virginia
    Chiang, Yiyun
    Salone, Cedric
    Pica, Natalie
    Zhu, Yunfan
    Pratt, Natasha
    Nadimpalli, Gita
    Pershing, Suzann
    Wernecke, Michael
    Cunningham, Fran E.
    Kelman, Jeffrey A.
    Graham, David J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 200 - 200
  • [42] Integrating real-world data from Brazil and Pakistan into the OMOP common data model and standardized health analytics framework to characterize COVID-19 in the Global South
    Pinto, Elzo Pereira, Jr.
    Normando, Priscilla
    Flores-Ortiz, Renzo
    Afzal, Muhammad Usman
    Jamil, Muhammad Asaad
    Bertolin, Sergio Fernandez
    Oliveira, Vinicius de Araujo
    Martufi, Valentina
    de Sousa, Fernanda
    Bashir, Amir
    Burn, Edward
    Ichihara, Maria Yury
    Barreto, Mauricio L.
    Salles, Talita Duarte
    Prieto-Alhambra, Daniel
    Hafeez, Haroon
    Khalid, Sara
    JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2023, 30 (04) : 643 - 655
  • [43] Immunogenicity and real-world effectiveness of COVID-19 vaccines in Lebanon: Insights from primary and booster schemes, variants, infections, and hospitalization
    Moghnieh, Rima
    Haddad, Wajdi
    Jbeily, Nayla
    El-Hassan, Salam
    Eid, Shadi
    Baba, Hicham
    Sily, Marilyne
    Saber, Yara
    Abdallah, Dania
    Bizri, Abdul Rahman
    Sayegh, Mohamed H.
    PLOS ONE, 2024, 19 (09):
  • [44] Risk Assessment of COVID-19 Cases in Emergency Departments and Clinics With the Use of Real-World Data and Artificial Intelligence: Observational Study
    Logaras, Evangelos
    Billis, Antonis
    Kokkinidis, Ilias Kyparissidis
    Ketseridou, Smaranda Nafsika
    Fourlis, Alexios
    Tzotzis, Aristotelis
    Imprialos, Konstantinos
    Doumas, Michael
    Bamidis, Panagiotis
    JMIR FORMATIVE RESEARCH, 2022, 6 (11)
  • [45] COVID-19 and Obstructive Lung Disease: Are COPD and Asthma Risk Factors for Severe COVID-19? Evaluating the Data from the Largest Health System in New York State
    Schwartz, J.
    Birnbaum, B. R.
    Ballenberger, M. C.
    Mahmoud, O. H.
    Mina, B. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [46] Treatment adherence in psoriatic patients during COVID-19 pandemic: Real-world data from a tertiary hospital in Greece
    Vakirlis, E.
    Bakirtzi, K.
    Papadimitriou, I.
    Vrani, F.
    Sideris, N.
    Lallas, A.
    Ioannides, D.
    Sotiriou, E.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (11) : E673 - E675
  • [47] Hospital admissions and place of death prior and during COVID-19: Real-world data from a Brazilian cancer center
    Lucia Nascimento, Karla Lucia
    Philip, Errol James
    Sacchi, Luana
    Pereira, Juliana
    Nazario, Jose
    Matos Neto, Joao Nunes
    Bergerot, Cristiane Decat
    Lee, David
    Bergerot, Paulo Gustavo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [48] Real-world patient data on immunity and COVID-19 status of patients with MPS, Gaucher, and Pompe diseases from Turkey
    Kilavuz, S.
    Kor, D.
    Bulut, F. D.
    Serbes, M.
    Karagoz, D.
    Altintas, D. U.
    Bisgin, A.
    Seydaoglu, G.
    Mungan, H. N. O.
    ARCHIVES DE PEDIATRIE, 2022, 29 (06): : 415 - 423
  • [49] A Proactive Approach to Identify the Exposure Risk to COVID-19: Validation of the Pandemic Risk Exposure Measurement (PREM) Model Using Real-World Data
    Grima, Simon
    Rupeika-Apoga, Ramona
    Kizilkaya, Murat
    Romanova, Inna
    Gonzi, Rebecca Dalli
    Jakovljevic, Mihajlo
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2021, 14 : 4775 - 4787
  • [50] Vaccine effectiveness against severe acute respiratory infections (SARI) COVID-19 hospitalisations estimated from real-world surveillance data, Slovenia, October 2021
    Vitek, Marta Grgic
    Klavs, Irena
    Ucakar, Veronika
    Serdt, Mojca
    Mrzel, Maja
    Vrh, Marjana
    Fafangel, Mario
    EUROSURVEILLANCE, 2022, 27 (01)